Cagrilintide

Roche Holding's MUSETTE Phase III trial demonstrated strong efficacy of the approved 600 mg dose of OCREVUS for multiple sclerosis, reinforcing its position in the treatment landscape.

Roche has entered into a $5.3 billion collaboration with Zealand Pharma to co-develop petrelintide, a promising amylin analog for obesity treatment, both as monotherapy and in combination with Roche's incretin asset CT-388.

Novo Nordisk is expanding its GLP-1 research beyond diabetes and obesity, investigating the potential therapeutic applications for addiction treatment.

Novo Nordisk introduces NovoCare Pharmacy, a direct-to-patient delivery service offering all Wegovy dose strengths at $499 per month for cash-paying and eligible commercially insured patients without coverage.

AbbVie makes its strategic entry into the obesity therapeutics market through a $350 million upfront licensing agreement with Danish biotech Gubra for their amylin analog GUB014295.